A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
NCT07795814
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Heart Failure With Preserved Ejection Fraction
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 30 to 84 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Edgewise Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Local Institution - 1 · Birmingham, AL
California · 1
- Local Institution - 4 · Vista, CA
Illinois · 1
- Local Institution - 5 · Peoria, IL
Louisiana · 1
- Local Institution - 7 · Houma, LA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.